Oral infigratinib, a FGFR1-3 inhibitor, shows promise in improving growth in children aged 3-11 with achondroplasia. Phase 2: 72 kids. #GrowthBreakthrough PMID:39555818, N Engl J Med 2025, @NEJM https://doi.org/10.1056/NEJMoa2411790 #Medsky 🧪
https://doi.org/10.1056/NEJMoa2411790
No description available
doi.org
March 10, 2025 at 11:10 AM
Oral infigratinib, a FGFR1-3 inhibitor, shows promise in improving growth in children aged 3-11 with achondroplasia. Phase 2: 72 kids. #GrowthBreakthrough PMID:39555818, N Engl J Med 2025, @NEJM https://doi.org/10.1056/NEJMoa2411790 #Medsky 🧪